Jiangsu Jibeier Pharmaceutical Co., Ltd.

Shanghai Stock Exchange 688566.SS

Jiangsu Jibeier Pharmaceutical Co., Ltd. Revenue Per Share for the year ending December 31, 2023: USD 0.65

Jiangsu Jibeier Pharmaceutical Co., Ltd. Revenue Per Share is USD 0.65 for the year ending December 31, 2023, a 27.60% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.
  • Jiangsu Jibeier Pharmaceutical Co., Ltd. Revenue Per Share for the year ending December 31, 2022 was USD 0.51, a 18.28% change year over year.
  • Jiangsu Jibeier Pharmaceutical Co., Ltd. Revenue Per Share for the year ending December 31, 2021 was USD 0.43, a -7.49% change year over year.
  • Jiangsu Jibeier Pharmaceutical Co., Ltd. Revenue Per Share for the year ending December 31, 2020 was USD 0.46, a 11.30% change year over year.
  • Jiangsu Jibeier Pharmaceutical Co., Ltd. Revenue Per Share for the year ending December 31, 2019 was USD 0.42, a -17.25% change year over year.
Key data
Date Revenue Per Share Dividend Per Share Free Cash Flow Per Share Return on Assets (ROA)
Market news
SV Wall Street
Shanghai Stock Exchange: 688566.SS

Jiangsu Jibeier Pharmaceutical Co., Ltd.

CEO Mr. Zhongyi Geng
IPO Date May 18, 2020
Location China
Headquarters High-tech Industrial Development Zone
Employees 1,445
Sector Healthcare
Industries
Pharmaceuticals Biotechnology
Description

Jiangsu Jibeier Pharmaceutical Co., Ltd., a pharmaceutical company, engages in the research, development, production, and sale of chemical preparations, proprietary Chinese medicine preparations, and bulk medicines. The company's products cover various therapeutic areas, such as improving white blood cells, enhancing immunity, treating joint diseases, anti-hypertension, anti-eye infections, treating bronchitis, protecting liver function, etc. It is also developing drugs for the treatment of depression, tumors, stomach diseases, and other diseases. The company was founded in 2001 and is based in Zhenjiang, China.

StockViz Staff

February 2, 2025

Any question? Send us an email